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Abstract
Background: Limited data exist on the incidence and outcome of early infection after orthotopic heart trans-
plantation (OHT). The purpose of this study was to describe characteristics and outcomes of OHT recipients
with an early infection and to identify predictors of such infections.
Methods: This retrospective, single-center study included patients greater than 18 years of age who underwent
OHT from February 2009 to May 2014 and had an infection within 30 days of transplantation. Patient
demographics, clinical variables, and outcomes were collected. Multivariable logistic regression was performed
to identify independent predictors of infection.
Results: Of the 172 eligible OHT recipients, 51 (29.7%) had an early infection. The median time to diagnosis
was five days, with gram-negative organisms being slightly more common (58.2%). No differences in mortality
rate, rejection, or re-admission were found between the groups. Longer durations of mechanical ventilation and
lengths of stay were found in the infection group (p< 0.001). Patients with an early infection also had a higher
incidence of mechanical circulatory support, history of drive-line infection, longer duration of mechanical
ventilation, continuous renal replacement therapy (CRRT), and delayed chest closure (p< 0.05 for all). Pre-
OHT left-ventricular assist device (adjusted odds ratio [AOR] 2.53; 95% confidence interval [CI] 1.015–6.286;
p< 0.046), pre-OHT extracorporeal membrane oxygenation (AOR 14.10; 95% CI 1.38–150.5; p= 0.026) and
post-OHT CRRT (AOR 3.98; 95% CI 1.67–9.52; p= 0.002) were found to be independent risk factors for an
early infection. A total of 90% of the available susceptibility panels for the gram-negative isolates (26/29) were
resistant to the standard peri-operative cephalosporin given.
Conclusions: Prior mechanical circulatory support and the acute need for CRRT may predispose OHT patients
to an infection early in the post-operative period. Evaluation of peri-operative antimicrobial prophylaxis, based
on an individual center’s resistance panels, may be warranted.
Keywords: infection; left ventricular assist device; orthotopic heart transplantation
S ince the first heart transplantation in 1967, theprocedure has grown worldwide to a total of 120,991
adult recipients as of June 2016 [1]. With advances in im-
munosuppression regimens and surgical technique, the overall
risk of rejection and survival have improved [2,3]. However,
infectious complications remain and may influence survival,
rejection, and re-admission rates.
According to the Scientific Registry of Transplant Recipients
(SRTR) and Organ Procurement and Transplantation Network
(OPTN) Annual Data Report in 2015, infection was the most
common cause of death (2.3% of the series) at one year after
OHT [2]. Infection within the first month post-OHT has dem-
onstrated even higher mortality rates (13%–60%) in some
studies [4,5]. Bacterial infections continue to be the most com-
mon type of severe infections [4,6–9], with gram-positive or-
ganisms being the primary infecting pathogens [6]. Interest in b-
lactamase-producing Enterobacteriaceae and fungal infections
in this patient population also has emerged recently [10–12].
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Although the incidence and type of infection post-OHT
have been reported [1,2,4,5], the characteristics of patients
who develop infection in the early transplant period have not
been described well. Descriptions of the organisms cultured,
sites of infection, and risk factors contributing to these early
infections are lacking. Additionally, the impact of early in-
fection on clinical outcomes is unclear. The purpose of this
study was to describe the characteristics and outcomes of
OHT recipients with an infection identified within 30 days of
transplantation. Secondary objectives were identifying fac-
tors associated with an early infection.
Patients and Methods
This retrospective, single-center cohort study was per-
formed at Barnes-Jewish Hospital, a 1,315-bed tertiary-care
academic medical center that is the affiliated teaching hos-
pital for Washington University School of Medicine in St.
Louis. The Washington University School of Medicine Hu-
man Research Protection Office and the Protocol Review and
Monitoring Committee approved this study.
The Barnes-JewishHospital medical informatics systemwas
queried to identify OHT recipients who were admitted between
February 2009 and May 2014. To be included in the early-
infection cohort, OHT recipients had to be at least 18 years of
age, have a positive culture with one or more organism(s), and
meet the specified definition of infection within 30 days post-
transplant. Exclusion criteria included death within 48 hours of
transplant, missing data in the medical chart, transplant per-
formed at an outside hospital, or active infection requiring in-
travenous antibiotics at the time of transplantation.
Electronic medical records were searched to identify
demographic data, immunosuppressive and antimicrobial
regimens received, site of positive culture(s), organism(s)
cultured, and time to first positive culture. Baseline co-
morbidities were identified via the International Classifi-
cation of Disease 9th revision codes [13,14]. Hospital and
intensive care unit (ICU) length of stay (LOS), rejection
occurrence, re-admission dates, and mortality data also were
collected.
Definitions
All documented infections were confirmed on the basis of
clinical signs and symptoms of infection in correlation with a
positive culture and an infectious disease consultation when
applicable. Pneumonia was defined as the presence of new or
worsening radiographic pulmonary infiltrates along with
clinical findings suggesting infection (leukocytosis, fever,
purulent sputum) in addition to growth of organism(s) in
cultures obtained through sputum or tracheal aspirate, with
hospital-acquired pneumonia (HAP) occurring 48 hours or
more after admission and ventilator-associated pneumonia
(VAP) occurring 48 hours or more after endotracheal intu-
bation. Nosocomial tracheobronchitis was defined when
clinical findings suggested a pulmonary infection with a
positive respiratory culture without a new lung infiltrate
[4,15]. Urinary tract infection (UTI) was diagnosed in pa-
tients without an indwelling urethral catheter when docu-
mentation of pyuria or bacteremia in addition to a positive
urine culture (>105 colony-forming units [CFU]/mL) was
found [4]. In patients with indwelling urethral catheters, ‡105
CFU/mL of one or more bacterial species in a urine specimen
had to be noted [16]. Blood stream infection (BSI) was de-
fined as one or more organisms isolated from at least two
consecutive blood cultures. In cases involving micro-
organisms of doubtful significance (e.g., Bacillus spp.,
coagulase-negative Staphylococcus spp.), clinically relevant
episodes were noted only if evidence of clinical infection was
present in addition to an infectious disease consultation di-
agnosis.
Multi-drug resistance (MDR) for Staphylococcus aureus,
Enterococcus spp., Enterobacteriaceae, Pseudomonas aeru-
ginosa, and Acinetobacter spp. were defined according to
standardized terminology [17]. Our institution’s microbiology
laboratory reports susceptibility results of AmpC-stable b-
lactamases as well as non-b-lactam agents for Enterobacter
spp., Serratia spp., andCitrobacter freundii. Default resistance
to AmpC-labile agents (ceftriaxone, aztreonam, piperacillin/
tazobactam) is reported for the aforementioned bacterial iso-
lates, as at our center, 85% have inducible AmpC resistance
and 11% have stable high-level AmpC expression [18].
Appropriate antimicrobial therapy was defined as an ini-
tially prescribed regimen with activity against the identified
pathogen based on in vitro susceptibility testing and admin-
istration within 24 hours of culture. Acute cellular rejection
(ACR) was defined as a biopsy specimen post-OHT dis-
playing Grade ‡2R/3a rejection [19].
Standard process of care
Peri-operative prophylaxis for OHT recipients includes
vancomycin and cefazolin intra-operatively, continued for
24 hours after chest closure. Heart transplant recipients at
our institution do not receive routine surveillance cultures
in the intra-operative or post-operative periods. Cultures
are obtained only when there is clinical evidence suggestive
of infection that may warrant treatment. Clinical evidence
of infection prompting an infectious work-up include fever,
leukocytosis, hypotension, and diagnostic imaging or other
hemodynamic measures suggestive of sepsis. Infectious
disease consultations generally are obtained on all trans-
plant recipients. The current immunosuppression protocol
at Barnes-Jewish Hospital is methylprednisolone intra-
operatively followed by mycophenolate mofetil (MMF),
tacrolimus, and methylprednisolone immediately post-
operatively. Patients who received induction therapy from
February 1, 2009 to August 2010 received anti-thymocyte
globulin and those operated on from August 2010 to May
2014 received basiliximab because of a change in institution
protocol. Patients received induction unless considered at
high risk for infection; i.e., on suppressive antibiotics prior
to transplantation.
Statistical analysis
Statistical analysis was completed using SPSS software,
version 22.0 (SPSS, Inc., Chicago, IL). Continuous data were
analyzed using the Student’s t-test for parametric data and
theMann-Whitney U test for nonparametric data. Categorical
data were analyzed with the w2 or the Fisher exact test. A
p value <0.05 was considered significant. Backwards step-
wise logistic regression was utilized to identify risk factors
independently associated with an early infection. Variables
significant at a p value £0.1 in the univariable analyses were
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entered in the stepwise multivariable logistic regression
model.
Results
A total of 185OHTs were performed during the study
period. Thirteen patients were excluded, leaving 172 patients
for analysis. Early infection criteria were met in 51 patients
(29.7%) (Fig. 1). The majority of the patients were Caucasian
males, younger than 65 years, with an idiopathic cardiomy-
opathy diagnosis. A significantly higher percent of patients
in the early infection cohort received extracorporeal mem-
brane oxygenation (ECMO) before OHT (11.8% vs. 0.8%;
p = 0.003), were left-ventricular assist device (LVAD) ex-
plants (66.7% vs. 30.6%; <0.001), and had histories of drive-
line infection (23.5% vs. 10.7%; p = 0.035) (Table 1). When
further analyzed by type of infection, no differences in de-
mographic data were found.
No difference in induction therapy was noted between the
early-infection and no early-infection cohorts. The primary
agent utilized was basiliximab in both groups. All patients
received maintenance therapy with tacrolimus, MMF, and
steroids per protocol. Patients in the infection cohort had a
higher incidence of continuous renal replacement therapy
(CRRT) after OHT, delayed chest closure, ECMO after OHT,
and a longer duration of mechanical ventilation (p < 0.05)
(Table 2).
Early infection cohort
The median temperature at the time of infection diagnosis
was 37.3C (interquartile range [IQR] 36.6–37.9C). Of note,
24 patients (47%) were on CRRT at the time of their infection
diagnosis, potentially masking the presence of a fever. The
median white blood cell (WBC) count at the time of infection
diagnosis was 23 · 103/mm3 (IQR 17.5–28.7· 103/mm3).
The majority of patients (78.4%) were receiving at least one
vasopressor. The median time to infection diagnosis was
five days (IQR 2.1–8.7 d).
A total of 67 organisms were identified in the 51 patients
with an early infection (Table 3). The most prevalent or-
ganisms were gram-negative bacteria (n= 39; 58.2%) with
fewer gram-positive organisms (n= 20; 29.9%). The most
common organisms were Staphylococcus spp., Enterobacter
spp., and Escherichia coli. Twenty-four MDR pathogens
(47%) were identified (20 gram-negative, two methicillin-
resistant S. aureus, two vancomycin-resistant Enterococci).
The most prevalent infection was pneumonia (n = 24; 47%;
19 VAP, five HAP) followed by BSI (n = 0; 19.6%) and UTI
(n = 7; 13.7%). Other infections were ventricular-assist de-
vice (VAD) pocket (n= 3; 5.8%), tracheobronchitis (n = 2;
3.9%), Clostridium difficile diarrhea (n = 2), and mediastini-
tis, groin seroma, pericarditis, and pacemaker (n = 1 each;
2.0%). Of the 24 pneumonia episodes, the organisms most
often isolated were gram-negative species with a median time
to infection of 4.3 days. Of note, patients with pneumonia had
a longer median mechanical ventilation duration of 9.5 (IQR
5.4–15.7) days compared with 2.8 (IQR 0.7–5.1) days in the
patients with other sites of infection (p<0.001). Additionally,
the median mechanical ventilation duration for patients with
pneumonia was significantly longer than for the non-infected
group (9.5 vs. 1.8 days; IQR0.8–3.6 days; p<0.0001). Themost
common BSI organisms were Serratia marcescens (n=3; 30%)
and Enterobacter cloacae (n=2; 20%) with a median time to
infection of 5.3 days. Escherichia coli and Pseudomonas aer-
uginosa (n=2; 28.6% each) were the most common UTI or-
ganisms with a median time to infection of nine days. The
median duration ofmechanical ventilation prior to a diagnosis of
a non-respiratory infection was four days. This was not signif-
icantly different from those with a respiratory infection.
Antimicrobial therapy
Standard peri-operative antimicrobial prophylaxis was ad-
ministered to 75% of patients who sustained an early infection
when patient allergies or previous culture history did not cause
divergence. The remaining 25% received broader coverage
with linezolid in the case of vancomycin intolerance and az-
treonam or meropenem for cephalosporin intolerance. Of
the 33 patients with gram-negative isolates, 29 (88%) had
susceptibility panels available for assessment. Notably, a to-
tal of 26 (90%) of the available susceptibility panels for the
gram-negative isolates, which included Citrobacter freundii,
Enterobacter spp., Escherichia coli, Klebsiella pneumoniae,
Proteus spp., Pseudomonas aeruginosa, and Serratia mar-
cescens, showed resistance to cefazolin. The median time to
FIG. 1. Adult orthotopic heart transplant (OHT) recipients from Barnes-Jewish Hospital were assessed for study inclu-
sion. Based on the inclusion criteria, 172 patients were eligible for analysis, with 51 patients meeting the criteria for early
infection.
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positive culture in this group was 1.5 days. Overall, inap-
propriate antimicrobial treatment was noted in 12 patients
(24%).
Outcomes
No differences in the mortality rate at 30 days or one year
were found. The median time to death was shorter in the
infection cohort although not significantly so (41.6 vs.
470 days; p = 0.23). Three patients in the early infection
group died prior to hospital discharge as a result of sepsis
(n = 2) or primary graft dysfunction (PGD) (n = 1). One pa-
tient in the no-infection group died of PGD. Rejection rates
were similar in the two groups. Patients with an early infec-
tion had a longer ICU and hospital LOS (p < 0.001). No dif-
ferences in 30-day re-admission rate were found (Table 4).
Risk Factors for Early Infection
The following variables in the univariable analyses with a
p value <0.1 were entered in a backwards stepwise logistical
regression analysis: LVAD (with and without drive-line in-
fection), ECMO (pre- and post-OHT), delayed chest closure,
and CRRT. This analysis revealed that that pre-OHT LVAD
Table 1. Baseline Characteristics of Early Infection Cohort vs. No Early Infection Cohorta
Variable Early infection (n= 51) No early infection (n = 121) p
Race 0.284
Caucasian 35 ( 68.6) 96 (79.3)
African American 16 ( 31.4) 23 (19.0)
Asian 0 1 (0.8)
Native American 0 1 (0.8)
Age (y)b 53.9 ( 45–63) 54.4 (48–62) 0.873
>65 9 ( 17.6) 18 (14.9) 0.648
Male sex 37 ( 72.5) 79 (65.3) 0.353
Body Mass Index (kg/m2)b 28.4 ( 24.2–32.4) 27.6 (22.8–30.9) 0.289
‡35 8 ( 15.7) 16 (13.2) 0.670
Reason for orthotopic heart transplantation 0.157
Idiopathic 30 ( 58.8) 64 (52.9)
Ischemic cardiomyopathy 12 ( 23.5) 41 (33.9)
Valvular 5 ( 9.8) 3 ( 2.5)
Restrictive 2 ( 3.9) 3 ( 2.5)
Hypertrophic 2 ( 3.9) 5 ( 4.1)
Graft dysfunction 0 5 ( 4.1)
Co-morbidities
Coronary artery disease 23 ( 45.1) 55 ( 45.5) 0.966
Diabetes mellitus 27 ( 52.9) 55 (45.5) 0.369
Chronic obstructive pulmonary disease 8 ( 15.7) 19 (15.7) 0.998
Asthma 4 ( 7.8) 8 ( 6.6) 0.751
Prior ECMO during same hospitalization 6 ( 11.8) 1 ( 0.8) 0.003
Left-ventricular assist device (LVAD) explants 34 ( 66.7) 37 (30.6) <0.001
History of LVAD DL infection 12 ( 23.5) 13 (10.7) 0.035
Duration of antibiotic for DL infection (d)b 233.5 (153.5–705.25) 227 (81–503.5) 0.320
aAll values presented as n (%) unless otherwise noted.
bValues presented as median (interquartile range).
DL= drive line; ECMO: extracorporeal membrane oxygenation.
Table 2. Post-OHT Process-of-Care Variablesa
Variable Early infection (n = 51) No early infection (n = 121) p
Induction therapy
None 16 (31.4) 34 (28.1)
Basiliximab 28 (54.9) 68 (56.2) 0.889
Anti-thymocyte globulin 7 (13.7) 19 (15.7)
CRRT 29 (56.9) 18 (14.9) <0.001
Delayed chest closure 32 (62.7) 31 (25.6) <0.001
ECMO 9 (17.6) 3 ( 2.5) <0.001
Mechanical ventilation duration (d)b 5.27 ( 2.56–11.7) 1.68 ( 0.8–3.39) <0.001
aAll values presented as n (%) unless otherwise noted.
bValues presented as median (interquartile range).
CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation.
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(AOR 2.53; 95% CI 1.015–6.286; p<0.046), pre-OHT ECMO
(AOR 14.1; 95% CI 1.38–150.5; p= 0.026), and post-OHT
CRRT (AOR 3.98; 95% CI 1.67–9.52; p=0.002) were inde-
pendent risk factors for an early infection (Table 5). Further
analysis assessing the impact of a prior LVAD on the devel-
opment of an infection was performed. No significant dif-
ferences in the number of pneumonia, BSI, UTI, or wound
infections were found in patients with and without a LVAD.
Discussion
This study provides insight into the characteristics of OHT
recipients with an early infection. The incidence of early
infection found in this study (29.7%) is lower than that in
previous reports of infection within 30 days of heart trans-
plantation (48.6%), likely due to the requirement of a positive
culture for inclusion in our study [7]. Although gram-positive
bacteria have been the primary cause of infections in this
patient population historically, one study assessing more than
600 heart transplant recipients noted a P. aeruginosa infec-
tion rate as high as 43%, with the most common site of in-
fection being the lungs (35%) [4]. Similarly, gram-negative
organisms comprised the majority of the isolates in our
study (58.2%), with the lungs being the most prevalent site
of infection. Gram-positive infection still was prevalent
(30%) followed by fungal infection (9%). Significantly,
MDR pathogens were present in 47% of patients. Extended-
spectrum ESBL-producing gram-negative organisms have
been reported in 2.2% of heart transplant recipients [12],
whereas we noted two ESBL infections (3.9%).
The median time to early infection was less than a week in
our study, with lung infections prevailing at a median of five
days and blood cultures at a median of 1.5 days. In fact, all
patients but one met the infection criteria within 14 days of
transplant, suggesting this is the most critical time period to
prevent post-OHT infection. Montoya et al. [4] report median
times for infectious episodes to be 28 days for mediastinal
incisions, 48 days for bacteremia, and 65 days for pneumonia.
The differences may be attributable to the large percentage of
pre-OHT mechanical circulatory support in our study, as the
infection risks in this patient population are well known.
Our mortality rate in the early post-transplantation period
was less than 5% and was not different at one year, similar to
the findings in other published reports [2,8]. Although the
difference was not statistically significant, it should be rec-
ognized that the 30-day mortality rate was 4% in the infection
cohort and 0.8% in the no-infection cohort. The likelihood of
a Type II error in testing this difference is high. In addition,
rejection and re-admission were similar in the two groups.
Mechanical ventilation duration and LOS were longer in the
infection cohort; however, it remains unknown whether this
was a consequence of or a risk factor for infection. It is in-
tuitive to think that patients with pneumonia will require
longer mechanical ventilation. Likewise, patients with any
Table 3. Organisms Isolateda
Gram negative 39 (58.2%) Fungi 6 (9.0%)
Enterobacter cloacae 9 Candida spp. 3
Escherichia coli 7 C. albicans 2
Klebsiella pneumonia 5 C. tropicalis 1
Serratia marcesens 5 Aspergillus fumigatus 1
Pseudomonas
aeruginosa
4 Aspergillus niger 1
Haemophilus influenza 2
Yeast (unspecified) 1
Stenotrophomonas
maltophilia
2
Anaerobes 2 (3.0%)
Acinetobacter
calcoaceticus-
baumannii
1
Clostridium difficile 2
Citrobacter freundii 1
Enterobacter sp 1
Moraxella catarrhalis 1
Prevotella oris 1
Gram positive 20 (29.9%)
Staphylococcus spp. 11
S. aureus 8
S. epidermidis 2
S. lugdunensis 1
Beta-hemolytic
Streptococcus Group G
1
Beta-hemolytic
Streptococcus Group F
1
Beta-hemolytic
Streptococcus Group C
1
Brevibacterium spp. 1
Coryneform bacteria 1
Enterococcus faecium 2
Other Enterococcus spp. 1
Cocci (no speciation) 1
aSixteen patients (31.4%) had polymicrobial cultures.
Table 4. Outcomes of Early Infection Cohort vs. No Early Infection Cohorta
Variable Early infection (n = 51) No early infection (n = 121) p
Death
Median time to death (days)b 41.6 (13.9–736.6) 470.3 (192.3–801.5) 0.230
At 1 y 3 ( 5.9) 6 ( 5.0) 0.726
At 30 d 2 ( 3.9) 1 ( 0.8) 0.210
Rejection <60 d 8 (15.7) 17 ( 14.0) 0.781
Post-OHT intensive care unit length of stay (d)b 14.2 ( 6.8– 21.2) 5.6 ( 3.9– 7.9) <0.001
Post-OHT hospital length of stay (d) b 29.8 (17.7– 19.5) 14.7 ( 11.7– 19.5) <0.001
30-d re-admission 17 (33.3) 42 ( 34.7) 0.862
Infection 7 (41.1) 13 ( 31.0)
Other 10 (58.8) 29 ( 69.0)
aAll values presented as n (%) unless otherwise noted.
bValues presented as median (interquartile range).
OHT = orthotopic heart transplantation.
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infection may have a longer LOS, with the assumption that
they have a greater severity of illness requiring longer
treatment and monitoring. Regardless, we were unable to
establish causality between these important factors.
Predictors of an early infection in our study included the use
of mechanical circulatory support and the need for acute
CRRT. Induction immunosuppression, renal replacement
therapy, delayed chest closure, and the use of ECMO have
been associated with a possible increase in the risk of fungal
infections in OHT recipients [11,12]. However, these studies
were small and do not addresses whether these factors place
patients at risk for other bacterial infections [10,11,21] Pre-
vious LVAD-related infections have been noted to put patients
at risk formore invasive infections afterOHT,with continuous
antimicrobial treatment before, during, and after transplanta-
tion being associated with fewer relapses [20]. In our study,
more patients in the infection group had histories of drive-line
infections, but this did not remain a predictor of infection by
logistic regression analysis. This finding may suggest that the
presence of an LVAD alone (with or without a previous in-
fection) is a risk factor for post-OHT infection. Although de-
layed chest closure did not remain a predictor of infection in
our study, it is worth noting that fungal infections occurred in
only three of these patients, whereas gram-negative infections
(72%) prevailed. The three patients with delayed chest closure
who developed a fungal BSI (within 10–16 days) were all
LVAD explants, with one receiving chronic suppressive an-
tibiotics for a median of 80 weeks. Although this may be
important, because of the limited number of fungal infections
and study design limitations, we are unable to make definitive
recommendations on anti-fungal prophylaxis. However,
known risk factors for fungal infection, such as long-term
receipt of antibiotics [22], should be consideredwhen deciding
on prophylaxis in this patient population. Regarding routine
antibiotic prophylaxis, it is worth noting that in our study, 90%
of the susceptibility panels for the gram-negative isolates
showed resistance to our standard intra-operative and peri-
operative prophylaxis cephalosporin, cefazolin. Accordingly,
the median time to positive culture in this group experiencing
resistance was less than two days. A broader-spectrum ceph-
alosporin with adequate in vitro activity against the most
common organisms cultured, such as cefepime, may be war-
ranted in the early transplant period in these high-risk popu-
lations. Non-cephalosporin alternatives such as carbapenems
may be appropriate at centers with higher rates of ESBL-
producing organisms. Likewise, centers with lower rates of
AmpC-producing organisms may desire to use b-lactamase–
inhibiting agents, such as piperacillin/tazobactam.
There are several limitations of this study. This was a ret-
rospective cohort investigation and suffers from the potential
biases inherent to this design. The interpretation of posi-
tive culture significance, therapeutic management, and patient
outcome depends on the accuracy of the documentation. Ad-
ditionally, patients treated for culture-negative sepsis or sus-
pected clinical infections were not included. The majority of
the positive cultures were identified during the patient’s stay in
the ICU, and the incidence and impact of an early positive
culture outside of an ICU remains unknown. Furthermore, the
frequency and timing of any previously treated infections was
not assessed. It remains unknown if prior infections, outside of
chronic drive-line infections, increased the risk of post-OHT
infection in this study. In addition, the impact of nasogastric
tube application and receipt of enteral nutrition on the occur-
rence of pneumonia infections could not be assessed. Finally, as
this study was conducted at a single institution, the results may
not be applicable to other institutions.
In conclusion, this study has provided additional descrip-
tions of the OHT patient population with an infection in the
early post-operative period. Gram-negative organisms ac-
counted for the majority of isolates, with most common sites
of infection being the lungs and blood. Although no statisti-
cally significant differences in overall mortality, rejection, or
re-admission rates were seen, a longer LOS and duration of
mechanical ventilation were found in patients with an early
infection. The relative difference in the 30-day mortality rate
may support a modified approach to preventing infection in
higher-risk patients. Previousmechanical support and the need
for acuteCRRTmay place heart transplant recipients at risk for
an early infection. Evaluation of peri-operative antimicrobial
prophylaxis duration and selection based on an individual
center’s resistance panels may be warranted in these patients.
Author Disclosure Statement
No competing financial interests exist.
References
1. Lund LH, Edwards LB, Kucheryavaya AY, et al. The
Registry of the International Society for Heart and Lung
Transplantation: Thirty-First Official Adult Heart Trans-
plant Report – 2014; Focus Theme: Retransplantation. J
Heart Lung Trans 2014;3:996–1008.
2. Colvin M, Smith JM, Skeans MA, et al. OPTN/SRTR 2015
Annual Data Report: Heart. Am J Transplant 2017;17:286–
356.
3. George JF, Pamboukian SV, Tallaj JA, et al. Balancing
rejection and infection with respect to age, race, and gen-
der: Clues acquired from 17 years of cardiac transplantation
data. J Heart Lung Trans 2010;29:966–972.
4. Montoya JG, Giraldo LF, Efron B, et al. Infectious com-
plications among 620 consecutive heart transplant patients
at Stanford University Medical Center. Clin Infect Dis
2001;33:629–640.
5. Hsu RB, Chang CI, Fang CT, et al. Bloodstream infection
in heart transplant recipients: 12 year-experience at a uni-
versity hospital in Taiwan. Eur J Cardio-Thorac Surg 2011;
40:1362–1367.
Table 5. Multivariate Logistic Regression Analysis
for Predictors of Early Infection
Variable AOR (95% CI) p
Pre-OHT LVAD 2.53 (1.015–6.286) 0.046
Pre-OHT LVAD with
drive-line infection
1.16 (0.377–3.54) 0.799
Pre-OHT ECMO 14.40 (1.38–150.50) 0.026
Post-OHT ECMO 3.05 (0.587–15.80) 0.185
Post-OHT delayed
chest closure
1.69 (0.697–4.09) 0.246
Post-OHT CRRT 3.98 (1.670–9.52) 0.002
Hosmer-Lemes p = 0.99.
AOR= adjusted odds ratio; CI= confidence interval; CRRT= con-
tinuous renal replacement therapy; ECMO= extracorporeal membrane
oxygenation; LVAD= left-ventricular assist device; OHT=orthotopic
heart transplantation.
INFECTION AFTER HEART TRANSPLANTATION 521
D
ow
nl
oa
de
d 
by
 W
as
hi
ng
to
n 
U
ni
v 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
7/
18
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
6. Haddad F, Deuse T, Pham M, et al. Changing trends in
infectious disease in heart transplantation. J Heart Lung
Trans 2010;29:306–315.
7. Sanchez-Lazaro IJ, Almenar L, Blanes M, et al. Timing,
etiology, and location of first infection in first year after
heart transplantation. Transplant Proc 2010;42:3017–3019.
8. Van De Beek D, Kremers WK, Del Pozo JL, et al. Effect of
infectious disease on outcome after heart transplantation.
Mayo Clin Proc 2008;83:304–308.
9. Rostad CA, Wehrheim K, Kirklin JK, et al. Bacterial in-
fections following pediatric heart transplantation: Epide-
miology, risk factors, and outcomes. J Heart Lung
Transplant 2017;36:996–1003.
10. Rabin AS, Givertz MM, Couper GS, et al. Risk factors for
invasive fungal disease in heart transplant recipients. J
Heart Lung Transplant. 2015;34:227–232.
11. Tissot F, Pascual M, Hullin R, et al. Impact of targeted
antifungal prophylaxis in heart transplant recipients at high
risk for early invasive fungal infection. Transplantation
2014;97:1192–1197.
12. Bui KT, Mehta S, Khu TH, et al. Extended spectrum b-
lactamase-producing Enterobacteriaceae infection in heart
and lung transplant recipients and in mechanical circulatory
support recipients. Transplantation 2014;97:590–594.
13. International Classification of Diseases, Ninth Revision
(ICD-9). Rockville, MD: National Center for Health Sta-
tistics. Available at: https://www.cdc.gov/nchs/icd/icd9.
htm Accessed August 31, 2017.
14. HCUP Overview. Healthcare Cost and Utilization Project
(HCUP). July 2017. Rockville, MD: Agency for Healthcare
Research and Quality. Available at: www.hcup-us.ahrq.
gov/overview.jsp Accessed August 31, 2017.
15. American Thoracic Society (ATS) and Infectious Diseases
Society of America (IDSA). Management of adults with
hospital-acquired and ventilator-associated pneumonia:
2016 Clinical Practice Guidelines by the Infectious Dis-
eases Society of America and the American Thoracic So-
ciety. Clin Infect Dis 2016; 63:e61–e111.
16. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis,
prevention, and treatment of catheter-associated urinary
tract infection in adults: 2009 international clinical practice
guidelines from the Infectious Diseases Society of America
(IDSA). Clin Infect Dis 2010;50:625–663.
17. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-
resistant, extensively drug-resistant and pandrug-resistant
bacteria: An international expert proposal for interim
standard definitions for acquired resistance. Clin Microbiol
Infect 2012;18:268–281.
18. Dunne WM, Hardin DJ. Use of several inducer and sub-
strate antibiotic combinations in a disk approximation assay
format to screen for ampC induction in patient isolates of
Pseudomonas aeruginosa, Enterobacter spp., Citrobacter
spp., and Serratia spp. J Clin Microbiol 2005;43:5945–
5949.
19. Costanzo MR, Dipchand A, Startling R, et al. The Inter-
national Society of Heart and Lung Transplantation
Guidelines for the care of heart transplant recipients. J
Heart Lung Transplant 2010;29:914–956.
20. Simon D, Fischer S, Grossman A, et al. Left ventricular
assist device-related infection: Treatment and outcome.
Clin Infect Dis 2005;40:1108–1115.
21. Uribe LG, Corte´s JA, Granados CE, Montoya JG. Anti-
fungal prophylaxis following heart transplantation: sys-
tematic review. Mycoses 2014;57:429–436.
22. Pappas PG, Kauffman CA, Andes D, et al.; Infectious
Diseases Society of America. Clinical practice guidelines
for the management of candidiasis: 2009 update by the
Infectious Diseases Society of America. Clin Infect Dis
2009;48:503–535.
Address correspondence to:
Dr. Kendall C. Shultes
Belmont University
College of Pharmacy
1900 Belmont Boulevard
Nashville, TN 37212-3757
E-mail: kcshultes06@gmail.com
522 SHULTES ET AL.
D
ow
nl
oa
de
d 
by
 W
as
hi
ng
to
n 
U
ni
v 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
7/
18
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
